3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
9
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
64
pembrolizumab
48
Fluorouracil
44
Capecitabine
38
Nivolumab
33
Leucovorin
32
Paclitaxel
28
Trastuzumab
19
Docetaxel
18
Cisplatin
18
S 1 (combination)
16
Bevacizumab
15
Ramucirumab
13
Irinotecan
13
Drug Therapy
13
tislelizumab
12
Cyclophosphamide
12
fludarabine
10
Carboplatin
10
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
8
sintilimab
8
Specimen Handling
8
Biopsy
8
atezolizumab
7
Surgical Procedures, Operative
7
Gemcitabine
7
zolbetuximab
6
durvalumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
AZD9833
×
1 year
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled